Molecular structure of Cabergoline, CAS Number: 81409-90-7
Cabergoline (CAS 81409-90-7)
Alternate Names:
Cabaser; Dostinex; (8β)-N-[3-(Dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propen-1-yl)-ergoline-8-carboxamide
Application:
Cabergoline is a D2-like agonist
CAS Number:
81409-90-7
Purity:
≥98%
Molecular Weight:
451.60
Molecular Formula:
C26H37N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Cabergoline is a selective D2DR (D2-like receptor) agonist, similarly displaying a high affinity for several serotonin receptor subtypes. Cabergoline exhibits an inhibitory effect of the secretion of prolactin and growth hormone and may act to reverse levodopa-induced dyskinesias in Parkinsonian monkeys. Cabergoline is an activator of D3DR.
Cabergoline (CAS 81409-90-7) References
- Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content. | Calon, F., et al. 1999. Neurochem Int. 35: 81-91. PMID: 10403433
- Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-monkeys. | Goulet, M., et al. 2000. Prog Neuropsychopharmacol Biol Psychiatry. 24: 607-17. PMID: 10958154
- Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. | Calon, F., et al. 2002. Prog Neuropsychopharmacol Biol Psychiatry. 26: 127-38. PMID: 11853103
- The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. | Yoshioka, M., et al. 2002. Neurosci Res. 43: 259-67. PMID: 12103444
- Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. | Tanaka, K. and Ogawa, N. 2005. Neurosci Res. 51: 9-13. PMID: 15596235
- Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. | Sharif, NA., et al. 2009. Exp Eye Res. 88: 386-97. PMID: 18992242
- Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans. | Li, H., et al. 2021. Pharmacol Res. 163: 105220. PMID: 33007422
- Therapeutic activity of sarpogrelate and dopamine D2 receptor agonists on cardiovascular and renal systems in rats with alloxan-induced diabetes. | Fouad Shalaby, MA., et al. 2021. BMC Pharmacol Toxicol. 22: 64. PMID: 34702339
- Protective Role of Sarpogrelate in Combination with Bromocriptine and Cabergoline for Treatment of Diabetes in Alloxan-induced Diabetic Rats. | Fouad Shalaby, M., et al. 2021. Curr Ther Res Clin Exp. 95: 100647. PMID: 34777640
- Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. | Rains, CP., et al. 1995. Drugs. 49: 255-79. PMID: 7729332
- Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. | Morissette, M., et al. 1998. Eur J Neurosci. 10: 2565-73. PMID: 9767387
Inhibitor of:
GH-1, GH-2, IGSF1, Placental GH, Placental lactogen I, Placental lactogen Iβ, Placental lactogen Iγ, PLP-A, PLP-H, PLP-J, PLP-K, Prolactin, and Thyrotropin-releasing hormone (TRH).Activator of:
Choriogonadotropin β, D2, D2DR, D3DR, D3NF, GRIN3, Inhibin β-C, Placental lactogen I, Plfr, PLP-J, and PLP-K.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cabergoline, 10 mg | sc-203864 | 10 mg | $300.00 | |||
Cabergoline, 50 mg | sc-203864A | 50 mg | $1055.00 |